Merck (MRK) announced that Health Canada has approved KEYTRUDA SC, a new subcutaneous formulation of pembrolizumab, Merck’s anti-PD-1 therapy. The approval is based on results from pivotal trial 3475A-D77, which compared pembrolizumab administered subcutaneously with pembrolizumab administered intravenously, both in combination with chemotherapy, in patients with treatment-naive metastatic squamous or non-squamous non-small cell lung cancer with no EGFR, ALK or ROS1 genomic tumor aberrations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK: